The Preferred Biotech Resource in Asia-Pacific
Vol 19, No 07, July 2015
Biotech in China
Kh-biotech cover


Eye on China


Conferences ListingConferences

Pharma Sales
2013 BIO Convention in China to connect biotech industry to the world’s 2nd largest biopharmaceutical market
The Biotechnology Industry Organization (BIO) announced the 3rd annual BIO® Convention in China, a sister event to the BIO International Convention that will bring together executives from biotechnology, pharmaceutical companies and investment firms from North America, Europe and Asia to meet and explore business opportunities in China, now the 2nd largest biopharmaceutical market in the world. The event will take place November 11–13, 2013 at the China National Convention Center in Beijing, China.

China has designated the biotechnology industry as one of seven pillar industries in its 12th Five Year Plan. Now in its 4th year, the Chinese government is dramatically expanding its resources for innovative biopharma research and development. This focus has been reflected in a dramatic expansion of Chinese companies in-licensing of Western-originated projects, with the number of in-licensing projects this year already exceeding the number of in-licenses, joint ventures (JVs) and mergers and acquisitions (M&A) last year.

“As China becomes a major force in the pharmaceutical market, the number of Chinese and Western collaborations has increased exponentially,” said Alan Eisenberg, Executive Vice President, Emerging Companies & Business Development at BIO. “As we prepare for the third BIO® Convention in China, we are more excited than ever about the opportunities that exist in China and are eager to provide the biotech industry with a platform to engage this quickly expanding biopharmaceutical market.”

Preliminary program topics for the 3rd annual BIO® Convention in China include science-focused sessions such as vaccines as well as the research and development of orphan drugs to treat rare diseases in China, and business-focused sessions exploring China’s private health care industry, early-stage VC funding in China, and partnering models between Chinese and Western companies.

The 2013 BIO® Convention in China will also feature one-on-one dialogues with biopharma industry executives who will discuss recent company successes, what keeps company executives up at night, and where the industry’s leading companies are headed in 2014.

Click here for the complete issue.